PBPierre R. Burkhard

Pierre R. Burkhard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pierre R. Burkhard has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sensorimotor hallucinations in Parkinson’s disease

    by Fosco Bernasconi, Eva Blondiaux, Jevita Potheegadoo, Giedre Stripeikyte, Javier Pagonabarraga, Helena Bejr-Kasem, Michela Bassolino, Michel Akselrod, Saul Martinez-Horta, Fred Sampedro, et al.

    Summary: Hallucinations in Parkinson’s disease (PD) are one of the most disturbing non-motor symptoms, affect half of the patients, and constitute a major risk factor for adverse clinical outcomes such as psychosis and dementia. Here we report a robotics-based approach, enabling the induction of a specific clinically-relevant hallucination (presence hallucination, PH) under controlled experimental conditions and the characterization of a PD subgroup with enhanced sensorimotor sensitivity for such robot-induced PH. Using MR-compatible robotics in healthy participants and lesion network mapping analysis in neurological non-PD patients, we identify a fronto-temporal network that was associated with PH. This common PH-network was selectively disrupted in a new and independent sample of PD patients and predicted the presence of symptomatic PH. These robotics-neuroimaging findings determine the behavioral and neural mechanisms of PH and reveal pathological cortical sensorimotor processes of PH in PD, identifying a more severe form of PD associated with psychosis and cognitive decline.


  • Open Access

    Illness Representations and Coping Strategies in Patients Treated with Deep Brain Stimulation for Parkinson’s Disease

    by Marc Baertschi, Nicolas Favez, João Flores Alves Dos Santos, Michalina Radomska, François Herrmann, Pierre R. Burkhard, Alessandra Canuto, Kerstin Weber, Paolo Ghisletta

    There is a debate on possible alterations of self-identity following deep brain stimulation for neurological disorders including Parkinson’s disease. Among the psychological variables likely to undergo changes throughout such a medical procedure, illness representations and coping strategies have not been the target of much research to this day. In order to remedy this, we investigated the dynamics of illness representations and coping strategies in an 18-month longitudinal study involving 45 patients undergoing deep brain stimulation for idiopathic Parkinson’s disease. Two research hypotheses were formulated and investigated through repeated measures of ANOVAs and structural equation modelling with full information maximum likelihood and Bayesian estimations. Representations of Parkinson’s disease as a cyclical condition and perception of control over the disease diminished after surgery. Use of instrumental coping strategies was not modified after deep brain stimulation. These changes were identified by SEM but not ANOVAs; their magnitude was nevertheless relatively small, implying general stability in representations. These findings suggest that psychological variables do not undergo major changes after deep brain stimulation for Parkinson’s disease.


  • Dyskinesia‐inducing lead contacts optimize outcome of subthalamic stimulation in Parkinson's disease

    by Walid Bouthour, Matthieu Béreau, Astrid Kibleur, André Zacharia, Emilie Tomkova Chaoui, Vanessa Fleury, Damien Benis, Shahan Momjian, Julien Bally, Christian Lüscher, et al.

    Background: Acute dyskinesias elicited by STN‐DBS, here referred to as stimulation‐induced dyskinesias, predict optimal clinical outcome in PD. However, it remains elusive whether stimulation‐induced dyskinesias can guide DBS programming.Objectives: Here, we characterized stimulation‐induced dyskinesias clinically and anatomically. We then tested whether dyskinesia‐inducing contacts could be effectively programmed using independent current source technology.Methods: We characterized stimulation‐induced dyskinesias with directional and ring stimulation retrospectively in 20 patients. We then localized dyskinesia‐inducing contacts by imaging coregistration and eventually programmed those contacts.Results: We elicited dyskinesias in half of our patients. Dyskinesia‐inducing contacts were mainly directional and were all located ventrally within the dorsolateral motor STN. When these dyskinesia‐inducing contacts were programmed using independent current source technology, dyskinesia disappeared and robust antibradykinetic effects were obtained.Conclusion: We confirm that stimulation‐induced dyskinesias are helpful clinical observations, which may guide programming of directional STN‐DBS in PD. © 2019 International Parkinson and Movement Disorder Society


  • Scan without evidence of dopaminergic deficit: A 10-year retrospective study

    by Nicolas Nicastro, Valentina Garibotto, Simon Badoud, Pierre R. Burkhard


  • Open Access

    E-selectin and vascular cell adhesion molecule-1 as biomarkers of 3-month outcome in cerebrovascular diseases

    by Sébastien Richard, Linnéa Lagerstedt, Pierre R. Burkhard, Marc Debouverie, Natacha Turck, Jean-Charles Sanchez

    Inflammation is known to worsen cerebral damage at the acute phase of stroke. In this setting, cell adhesion molecules (CAMs) play a crucial role mediating migration of immune cells into the infarcted area. However, their value in long-term outcome prediction for patients with cerebrovascular diseases (CVD) is less described. Levels of four CAMs (E-selectin, P-selectin glycoprotein ligand-1, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 (VCAM-1)) and six other known biomarkers (C-reactive protein (CRP), interleukin-6 (IL-6), N-terminal pro-brain natriuretic peptide (NT-proBNP), troponin I, vasopressin-neurophysin 2-copeptin, and S100 calcium-binding protein B) were measured in a population of patients presenting CVD. Blood collections for analysis were performed within different time windows after stroke onset: 0–6 h, 6–36 h, 2–3 days, 5–7 days, and 2–3 weeks. Independent associations with poor outcome at 3 months (modified Rankin Scale score > 2) were sought using univariate and multivariate analysis after adjustments for age and National Institute of Health Stroke Scale score. Predictive ability of each biomarker has also been assessed with ROC analysis. One hundred patients were prospectively included whom 75 presented with ischemic strokes, nine with hemorrhagic strokes and 16 with transient ischemic attacks. During the first 6 h after stroke onset, E-selectin was found to be an independent predictor of 3-month outcome (odds ratio (OR) =24; 95 % confidence interval (95 % CI), 2–354; p = 0.022) (area under the curve (AUC) =78 %), as was VCAM-1 during the third week after onset (OR = 8; 95 % CI, 2–37; p = 0.01) (AUC = 73 %). Associations remained after the exclusion of patients with hemorrhagic strokes and transient ischemic attacks. Independent associations with outcome were also found for CRP (OR = 5; 95 % CI, 1–22; p = 0.023) and IL-6 (OR = 5; 95 % CI, 1–17; p = 0.021) at 2–3 days and for NT-proBNP at 6–36 h (OR = 20; 95 % CI, 1–337; p = 0.04). E-selectin and VCAM-1 were independent predictors of outcome in a population of patients with CVD. The predictive capability of other biomarkers known to be indicators for prognosis also emerged, confirming the study’s robustness. CAMs levels could be considered as objective biological criteria for prognosis in CVD.


  • Establishing On-Site Reference Values for 123I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions

    by Nicolas Nicastro, Valentina Garibotto, Antoine Poncet, Simon Badoud, Pierre R. Burkhard

    To overcome the issue of reference values for DaTSCAN® requiring healthy controls, we propose an original approach using scans from individuals with non-degenerative conditions performed at one single center following the same acquisition protocol. From a cohort of 970 consecutive patients, we identified 182 patients with a clinical diagnosis of non-degenerative parkinsonism or tremor and a visually normal DATSCAN®. Caudate nucleus (C), putamen (P), and striatum (S) uptake values, C/P ratios, and asymmetry indexes (AI) were calculated using semi-quantitative methods. Outcomes were assessed according to age and gender, and reference limits were established using the percentile approach. A significant negative linear effect of age was found upon striatal nuclei uptake of 0.21–0.22 per decade (6.8 %/decade for striatum), whereas a potential gender influence proved unclear. Inferior reference limits were established at the 5th percentile. C/P ratios and AIs were not influenced by age or gender, and superior reference limits were set at the 95th percentile. We here propose a convenient approach to calculate site-specific reference limits for DaTSCAN® outcomes not requiring scanning healthy controls. The method appears to yield robust values that range within nearly identical limits as those obtained in healthy subjects.


    • 29 April 2015
      • Vol. 11  (472) , 955-6

    [Deep brain stimulation and "translational revolution": the central role of clinicians].

    by François J G Vingerhoets, Pierre R Burkhard, Renaud Du Pasquier, Pierre Pollak

  • Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis

    by Virginie Licker, Natacha Turck, Enikö Kövari, Karim Burkhardt, Mélanie Côte, Maria Surini‐Demiri, Johannes A. Lobrinus, Jean‐Charles Sanchez, Pierre R. Burkhard

    Parkinson's disease (PD) pathology spreads throughout the brain following a region‐specific process predominantly affecting the substantia nigra (SN) pars compacta. SN exhibits a progressive loss of dopaminergic neurons responsible for the major cardinal motor symptoms, along with the occurrence of Lewy bodies in the surviving neurons. To gain new insights into the underlying pathogenic mechanisms in PD, we studied postmortem nigral tissues dissected from pathologically confirmed PD cases (n = 5) and neurologically intact controls (n = 8). Using a high‐throughput shotgun proteomic strategy, we simultaneously identified 1795 proteins with concomitant quantitative data. To date, this represents the most extensive catalog of nigral proteins. Of them, 204 proteins displayed significant expression level changes in PD patients versus controls. These were involved in novel or known pathogenic processes including mitochondrial dysfunction, oxidative stress, or cytoskeleton impairment. We further characterized four candidates that might be relevant to PD pathogenesis. We confirmed the differential expression of ferritin‐L and seipin by Western blot and demonstrated the neuronal localization of gamma glutamyl hydrolase and nebulette by immunohistochemistry. Our preliminary findings suggest a role for nebulette overexpression in PD neurodegeneration, through mechanisms that may involve cytoskeleton dynamics disruption. All MS data have been deposited in the ProteomeXchange with identifier PXD000427 (http://proteomecentral.proteomexchange.org/dataset/PXD000427).